Edwards Lifesciences
1,188 hedge funds and large institutions have $53B invested in Edwards Lifesciences in 2021 Q2 according to their latest regulatory filings, with 137 funds opening new positions, 425 increasing their positions, 391 reducing their positions, and 82 closing their positions.
89% more funds holding in top 10
Funds holding in top 10: 9 → 17 (+8)
75% more call options, than puts
Call options by funds: $296M | Put options by funds: $169M
67% more first-time investments, than exits
New positions opened: 137 | Existing positions closed: 82
25% more capital invested
Capital invested by funds: $42.6B → $53B (+$10.5B)
4% more funds holding
Funds holding: 1,143 → 1,188 (+45)
9% more repeat investments, than reductions
Existing positions increased: 425 | Existing positions reduced: 391
0.59% more ownership
Funds ownership: 81.78% → 82.36% (+0.59%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$222M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$159M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$105M |
| 4 |
1832 Asset Management
Toronto,
Ontario, Canada
|
+$90.2M |
| 5 |
Man Group
London,
United Kingdom
|
+$78.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$403M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
-$239M |
| 3 |
A
AustralianSuper
Melbourne,
Australia
|
-$211M |
| 4 |
Janus Henderson Group
London,
|
-$85.1M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$63.3M |
EW Hedge Fund Activity: Q2 2021 in Review
1,188 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q2 2021, worth a combined $53B — up 25% from $42.6B a quarter earlier.
Buyers outnumbered sellers: 137 funds opened new EW positions and 82 closed out — a net gain of 55 holders — while 425 added to existing stakes and 391 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $222M. The largest seller was BlackRock, cutting an estimated $403M.
- 1,188 institutional investors held Edwards Lifesciences (EW) as of Q2 2021, up from 1,143 in Q1 2021.
- Funds reported $53B of Edwards Lifesciences stock for Q2 2021, up 25% quarter-over-quarter.
- 137 funds opened new Edwards Lifesciences positions in Q2 2021 and 82 closed out, a net change of +55 holders.
- The largest Edwards Lifesciences buyer in Q2 2021 was Fidelity Investments, an estimated $222M added.
- The largest Edwards Lifesciences seller in Q2 2021 was BlackRock, an estimated $403M sold.
Based on aggregated 13F filings for Q2 2021.